Casopitant mesylate (BioDeep_00000839646)

   


代谢物信息卡片


Casopitant mesylate

化学式: C31H39F7N4O5S (712.2529248)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=C(C=CC(=C1)F)C2CC(CCN2C(=O)N(C)C(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C.CS(=O)(=O)O
InChI: /m1./s1

描述信息

D018377 - Neurotransmitter Agents > D064729 - Neurokinin-1 Receptor Antagonists
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
D005765 - Gastrointestinal Agents > D000932 - Antiemetics
D002491 - Central Nervous System Agents
Casopitant mesylate (GW679769B) is a potent, selective, brain permeable and orally active neurokinin 1 (NK1) receptor antagonist. Casopitant mesylate is a second in the class of antiemetics that acts to antagonise the emetogenic effect of substance P. Casopitant mesylate is also a substrate and a weak-to-moderate inhibitor of CYP3A4. Casopitant mesylate can be used for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV)[1][2].

同义名列表

3 个代谢物同义名

Casopitant mesylate; GW679769B; Casopitant (mesylate)



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Paul J Hesketh, Oliver Wright, Gerardo Rosati, Mark Russo, Jeremey Levin, Stephen Lane, Vladimir Moiseyenko, Pierre Dube, Mikhail Kopp, Anatoly Makhson. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2012 Jul; 20(7):1471-8. doi: 10.1007/s00520-011-1235-4. [PMID: 21822913]
  • John W Bauman, Joyce M Antal, Laurel M Adams, Brendan M Johnson, Sharon C Murray, Bin Peng, Lyndon C Kirby, Peter F Lebowitz, Thomas C Marbury, Suzanne Swan, Maria Gutierrez. Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist. Investigational new drugs. 2012 Apr; 30(2):662-71. doi: 10.1007/s10637-010-9604-2. [PMID: 21188466]
  • Stefano Zamuner, Eugenii A Rabiner, Sofia A Fernandes, Massimo Bani, Roger N Gunn, Roberto Gomeni, Emilangelo Ratti, Vincent J Cunningham. A pharmacokinetic PET study of NK₁ receptor occupancy. European journal of nuclear medicine and molecular imaging. 2012 Feb; 39(2):226-35. doi: 10.1007/s00259-011-1954-2. [PMID: 21993526]
  • Mary K Ziejewski, Howard M Solomon, Dinesh Stanislaus, Robert L Clark, Tacey E White, April R Apostoli. The potential role for corticosterone in the induction of cleft palate in mice after treatment with a selective NK-1 receptor antagonist, casopitant (GW679769B). Birth defects research. Part B, Developmental and reproductive toxicology. 2012 Feb; 95(1):54-62. doi: 10.1002/bdrb.20341. [PMID: 22127931]
  • Federica Crivellente, Marcello Tontodonati, Nicola Fasdelli, Alessandro Casartelli, Roberto Dorigatti, Ivo Faustinelli, Patrizia Cristofori. NT-proBNP as a biomarker for the assessment of a potential cardiovascular drug-induced liability in beagle dogs. Cell biology and toxicology. 2011 Dec; 27(6):425-38. doi: 10.1007/s10565-011-9197-3. [PMID: 21823034]
  • Uday B Dandamudi, Laurel M Adams, Brendan Johnson, John Bauman, Shannon Morris, Sharon Murray, R Timothy Webb, Elaina Gartner, Raymond Hohl, Lionel D Lewis. Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. Cancer chemotherapy and pharmacology. 2011 Apr; 67(4):783-90. doi: 10.1007/s00280-010-1381-2. [PMID: 20556613]
  • Sabrina Pagliarusco, Silvia Martinucci, Ellenia Bordini, Lidia Miraglia, Domenico Cufari, Luca Ferrari, Mario Pellegatti. Tissue distribution and characterization of drug-related material in rats and dogs after repeated oral administration of casopitant. Drug metabolism and disposition: the biological fate of chemicals. 2011 Feb; 39(2):283-93. doi: 10.1124/dmd.110.035063. [PMID: 20978104]
  • Luca Ferrari, Daniela Reami, Marco Michi. Determination of casopitant and its three major metabolites in dog and rat plasma by positive ion liquid chromatography/tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2010 Nov; 878(29):2974-82. doi: 10.1016/j.jchromb.2010.09.001. [PMID: 20870467]
  • Stefano Zamuner, Brendan M Johnson, Sabrina Pagliarusco, Paolo Fina, Michela Peroni, Monica Fiore, Laurel M Adams, Sofia A Fernandes. Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine. British journal of clinical pharmacology. 2010 Oct; 70(4):537-46. doi: 10.1111/j.1365-2125.2010.03729.x. [PMID: 20840445]
  • Lidia Miraglia, Sabrina Pagliarusco, Ellenia Bordini, Silvia Martinucci, Mario Pellegatti. Metabolic disposition of casopitant, a potent neurokinin-1 receptor antagonist, in mice, rats, and dogs. Drug metabolism and disposition: the biological fate of chemicals. 2010 Oct; 38(10):1876-91. doi: 10.1124/dmd.110.033092. [PMID: 20622044]
  • Brendan M Johnson, Laurel M Adams, Ke Zhang, Shelby D Gainer, Lyndon C Kirby, Robert A Blum, Glen Apseloff, Royce A Morrison, Ralph A Schutz, Peter F Lebowitz. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. Journal of clinical pharmacology. 2010 Aug; 50(8):951-9. doi: 10.1177/0091270009353761. [PMID: 20124517]
  • Mario Pellegatti, Ellenia Bordini, Patrizia Fizzotti, Andy Roberts, Brendan M Johnson. Disposition and metabolism of radiolabeled casopitant in humans. Drug metabolism and disposition: the biological fate of chemicals. 2009 Aug; 37(8):1635-45. doi: 10.1124/dmd.109.026781. [PMID: 19420128]
  • Elisabeth Minthorn, Thomas Mencken, Andrew G King, Art Shu, David Rominger, Richard R Gontarek, Chao Han, Ramesh Bambal, Charles B Davis. Pharmacokinetics and brain penetration of casopitant, a potent and selective neurokinin-1 receptor antagonist, in the ferret. Drug metabolism and disposition: the biological fate of chemicals. 2008 Sep; 36(9):1846-52. doi: 10.1124/dmd.108.021758. [PMID: 18556439]